Abstract
Overview
Introduction
This analysis examines the current position and future outlook for
Schering-Plough in the ethical pharmaceutical sector. The profile encompasses
global strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Reasons to Purchase
- Benchmark Schering-Plough's performance against key rivals in the ethical
pharmaceutical sector
- Understand how Schering-Plough ethical sales are set to grow at a
2004-2010 CAGR of 7.4%, driven by Remicade, Zetia/Vytorin and the Intron
franchise
View Cart
